Overview
Lanka Hospitals operates a 367-bed multi-speciality tertiary hospital in Colombo, alongside diagnostics, pharmacies and healthcare training. The latest filing shows a materially stronger operating quarter: revenue expanded and the hospital converted a larger share of that activity into operating profit, while the balance sheet continued to build equity.
Price performance
At LKR 110.00 on 13 November 2026, LHCL was down 3.1% over one month while the ASPI rose 10.3%, but it was up 7.9% over one year against a 4.7% decline in the index. The shorter-term relative weakness therefore sits alongside a better one-year record than the market.
The share stands 41.7% of the way through its 52-week range, 12.6% below the high and 11.5% above the low. Sixty-day volatility was 7.5% below its own one-year norm, while recent volume was 9.7% above its 60-day norm, indicating quieter price swings but somewhat more trading activity than its recent baseline.
Its three-year record includes one fall of 15% or more, the deepest 47%, which has not yet recovered. Median daily turnover was about LKR 1.0 million over 60 sessions: a LKR 1 million order is about 99% of what trades on a typical day, a large part of a day's trading.
Valuation
At 12.6 times P/E, the market price represents 12.6 rupees for every rupee of trailing profit, modestly above the healthcare peer median of 11.44 times. The 1.44 times P/B means paying LKR 1.44 for each LKR 1 of net assets, also slightly above the sector median of 1.37 times; FY2025 ROE of 12.7% provides some support for paying above book value.
The 2.7% dividend yield exceeds the sector median of 1.7%, and the FY2025 dividend was LKR 3.00 per share after LKR 1.50 in each of FY2023 and FY2024. The payout has therefore increased rather than contracted, with earnings covering the trailing distribution 2.9 times.
Against its own history, LHCL is cheaper than 71% of days since March 2012 on P/B. A buyer at the current price is relying in part on the September quarter, which supplied 23.3% of trailing EPS; if that quarter had earned its year-ago net margin, the P/E would be 13.2 times rather than 12.6 times.
News and sentiment
Direct company coverage has been normal, but there were no material articles in the last 90 days. The notable disclosures were a trading halt pending disclosure reported on 22 May 2026, a chairman position change reported on 24 July, and the FY2025 final dividend.
The LKR 1.00 final dividend went ex-dividend on 3 June 2026 and was paid on 22 June. A buyer today does not receive that dividend.
Financials
September-quarter revenue rose 16.8% year-on-year to LKR 4.2 billion, while net profit increased 46.3% to LKR 608 million. Operating profit grew faster, up 73.8%, showing that the improvement was primarily operational rather than driven by below-the-line items.
Gross margin was 48.9% versus 43.8% a year earlier, operating margin was 18.0% versus 12.1%, and net margin was 14.4% versus 11.5%. September was the best of seven comparable September quarters for gross margin and among the best two of seven for operating margin, although net margin ranked a middling fourth of seven. The profit a share represents therefore benefited from unusually strong gross and operating execution, while the final conversion to net profit was less exceptional.
Below-the-line items reduced operating profit by LKR 151 million, compared with a much smaller drag a year earlier, so finance costs, tax and other non-operating items still absorbed part of the operating gain. Equity increased to LKR 17.0 billion from LKR 15.0 billion a year earlier. The latest balance sheet used 223.7 million shares, unchanged from the year-ago September filing, so the improvement in absolute profit was not diluted by a change in ordinary share count.
Risks
The largest practical risk is liquidity rather than balance-sheet strain: median daily turnover of about LKR 1.0 million makes a LKR 1 million transaction a large part of a typical session. This limits the ease with which a sizeable position can be built or exited.
The latest annual balance sheet was well covered, with a current ratio of 4.15 times, meaning it held more than four rupees of short-term assets, including receivables and inventories, for each rupee of bills due within a year. Interest cover was 36.01 times, meaning operating profit covered the interest bill many times, and cash conversion was 1.26 times, so FY2025 operating profit arrived as cash. These figures reduce financing risk, though the latest quarter's LKR 151 million below-the-line drag shows that final profit can still differ from operating performance.
As at 15 November 2026, Sri Lanka's backdrop included higher fuel prices and rupee weakness. These are economy-wide conditions rather than company disclosures, but they leave hospital operating costs and imported medical inputs as areas the available data cannot quantify.
Outlook
As at 15 November 2026, the next scheduled company event is the audited year-end filing for 31 December 2026, expected between 28 April and 3 June 2027. It will show whether the September quarter's unusually strong gross and operating margins carried into the final quarter and whether the operating gains remained cash-backed.
The available data does not identify any dated expansion, contract, capital action or regulatory decision that would otherwise change near-term earning power. Healthcare-sector discussion has focused on longer-term care demand and possible trade cooperation, but neither is evidence of a specific benefit to Lanka Hospitals.